Cargando…

New oral anti-coagulants versus vitamin K antagonists in high thromboembolic risk patients

BACKGROUND: Oral anticoagulant therapy (VKA) is nowadays the mainstay of treatment in primary and secondary stroke prevention in patients with atrial fibrillation. Given the limited risk-benefit ratio of vitamin K antagonists, pharmacological research has been directed towards the development of pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bellin, Annachiara, Berto, Patrizia, Themistoclakis, Sakis, Chandak, Aastha, Giusti, Pietro, Cavalli, Giacomo, Bakshi, Sumeet, Tessarin, Michele, Deambrosis, Paola, Chinellato, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6779249/ https://www.ncbi.nlm.nih.gov/pubmed/31589620 http://dx.doi.org/10.1371/journal.pone.0222762

Ejemplares similares

Statin use decreases coagulation in users of vitamin K antagonists
por: van Rein, Nienke, et al.
Publicado: (2016)

The impact of acute diarrhea on the coagulation status of patients with vitamin K antagonists
por: Schweinfurth, Johannes, et al.
Publicado: (2021)

High-quality and Fast Mapping of a Focal Atrial Tachycardia Arising from Koch’s Triangle
por: China, Paolo, et al.
Publicado: (2021)

Systematic Review on S-ICD Lead Extraction
por: Vio, Riccardo, et al.
Publicado: (2023)

Rivaroxaban and other non-vitamin K antagonist oral anticoagulants in the emergency treatment of thromboembolism
por: Goldstein, Patrick, et al.
Publicado: (2013)

Effective management of venous thromboembolism in the community: non-vitamin K antagonist oral anticoagulants
por: Patel, Raj
Publicado: (2016)

Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism
por: Bistervels, Ingrid M., et al.
Publicado: (2022)

Microbial Modulation of Coagulation Disorders in Venous Thromboembolism
por: Lichota, Anna, et al.
Publicado: (2020)

Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment
por: Bauersachs, Rupert M, et al.
Publicado: (2014)

Sepsis-Associated Disseminated Intravascular Coagulation and Thromboembolic Disease
por: Semeraro, Nicola, et al.
Publicado: (2010)

Use of Vitamins K antagonists in non-valvular atrial fibrillation thromboembolic risk prevention in Burkina Faso
por: Yameogo, Aristide Relwendé, et al.
Publicado: (2016)

Cost-Effectiveness Analysis of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Venous Thromboembolism in China
por: Sun, Ke-Xin, et al.
Publicado: (2021)

Efficacy and safety of non-vitamin K antagonist oral anticoagulants for venous thromboembolism: a meta-analysis
por: Zhuang, Yan, et al.
Publicado: (2021)

Coagulation changes and thromboembolic risk in COVID-19 obstetric patients
por: Benhamou, Dan, et al.
Publicado: (2020)

Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review
por: Mearns, Elizabeth S, et al.
Publicado: (2014)

New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events
por: Mekaj, Ymer H, et al.
Publicado: (2015)

Non-Vitamin K Antagonist Oral Anticoagulants in Medical Conditions at High Risk of Thromboembolism beyond Atrial Fibrillation
por: Hong, Keun-Sik
Publicado: (2019)

Many Good Reasons to Switch from Vitamin K Antagonists to Non-Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation
por: Botto, Giovanni Luca, et al.
Publicado: (2021)

Treatment with rivaroxaban and monitoring of coagulation profiles in two dogs with venous thromboembolism
por: UCHIDA, Mona, et al.
Publicado: (2020)

Venous thrombosis, thromboembolism, biomarkers of inflammation, and coagulation in coronavirus disease 2019
por: Thondapu, Vikas, et al.
Publicado: (2021)

Non-vitamin K antagonist oral anticoagulants in venous thromboembolism patients: a meta-analysis of real-world studies
por: Liu, Zhi-Yan, et al.
Publicado: (2022)

Associations between coagulation factor XII, coagulation factor XI, and stability of venous thromboembolism: A case-control study
por: Meng, Yan, et al.
Publicado: (2022)

Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist
por: Bamber, Luke, et al.
Publicado: (2015)

Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences
por: Lanitis, Tereza, et al.
Publicado: (2017)

Real-world data emulating randomized controlled trials of non-vitamin K antagonist oral anticoagulants in patients with venous thromboembolism
por: Yoon, Dongwon, et al.
Publicado: (2023)

Clinical features of patients with lung cancer accompanied by thromboembolism or disseminated intravascular coagulation
por: Kanaji, Nobuhiro, et al.
Publicado: (2018)

Thromboembolic and Bleeding Events in Transthyretin Amyloidosis and Coagulation System Abnormalities: A Review
por: Napolitano, Angela, et al.
Publicado: (2023)

Direct oral anticoagulants vs. vitamin K antagonists in patients with antiphospholipid syndrome: a systematic review and meta-analysis
por: Shah, Bidhan Bikram, et al.
Publicado: (2023)

Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis
por: Dranitsaris, George, et al.
Publicado: (2017)

Thromboembolic and major bleeding events in relation to perioperative bridging of vitamin K antagonists in 649 fast-track total hip and knee arthroplasties
por: Jørgensen, Christoffer C, et al.
Publicado: (2017)

Factor Xa inhibitors versus vitamin K antagonist in morbidly obese patients with venous thromboembolism: a systematic review and meta-analysis
por: Park, Dae Yong, et al.
Publicado: (2023)

Vitamin K: the effect on health beyond coagulation – an overview
por: Vermeer, Cees
Publicado: (2012)

Coagulation and fibrinolysis in hyperparathyroidism secondary to vitamin D deficiency
por: Elbers, Laura P B, et al.
Publicado: (2018)

Coagulation Factor Plasma Levels Following Administration of a 4-Factor Prothrombin Complex Concentrate for Rapid Vitamin K Antagonist Reversal in Japanese Patients
por: Yasaka, Masahiro, et al.
Publicado: (2018)

Therapeutic Role of Sirtuins Targeting Unfolded Protein Response, Coagulation, and Inflammation in Hypoxia-Induced Thrombosis
por: Sadia, Khan, et al.
Publicado: (2021)

Platelet Count and Major Bleeding in Patients Receiving Vitamin K Antagonists for Acute Venous Thromboembolism, Findings From Real World Clinical Practice
por: Giorgi-Pierfranceschi, Matteo, et al.
Publicado: (2015)

Comparison Between Non–vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism
por: Chen, Dong-Yi, et al.
Publicado: (2021)

Non-vitamin K antagonist oral anticoagulants in adults with a Fontan circulation: are they safe
por: Yang, Hayang, et al.
Publicado: (2019)

Saponins as Modulators of the Blood Coagulation System and Perspectives Regarding Their Use in the Prevention of Venous Thromboembolic Incidents
por: Olas, Beata, et al.
Publicado: (2020)

Platelet, Fibrinolytic and Other Coagulation Abnormalities in Newly-Diagnosed Patients with Chronic Thromboembolic Pulmonary Hypertension
por: Vrigkou, Eleni, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a3i1kooguufgk2gm89fgoen144